Sulforaphane [1-isothiocyanato-4-(methylsulflnyl)butanej was recently isolated from one variety ofbroccoli as the major and very potent inducer of phase 2 detoxication enzymes in murine he a cells in culture. Since phase 2 enzyme inducti is often asated With reduced ptbilit of animais and their cells to the toxic and ic effects of carcinogens and other electrophiles, it was i t to ash whether sulforaphane could block c ical carngeness. In this paper we report that sulfphane and three synthetic analogues, designed as potent phase 2 enzyme inducers, block the formation of ammary tumors in Sprague4Dawley rats treated with single doses of 9,10-dimethyl-1,2-benzanthracene. The anaogues are exo-2-acety-exo-6-isothiocyanatoorbornane, endo-2-acetyl-exo-6-isothiocyanatonorbornane, and exo-2-acetyl-exo-5-isothiocyanatonorbornane. When sulforaphane and exo-2-acetyl-ero-6-isothicyanatonorbornane were administered by gavage (75 or 150 amol per day for 5 days) around the time of exposure to the carcinogen, the incidence, multipcty, and weight ofmammary tumors were g ntly reduced, and their development was delayed. The anages endo-2-acetyl-exo-6-isothocyanatonorbornane and exo-2-acetyl-exo-5-iothlocyanatonorbornane were less potent protectors. Thus, a class of functioalized isotdocyanates with an rcgenic Properties has been identified. These results validate the thesis that inducers of phase 2 enzymes in cultured cells are likely to protect against carcinogenesis.
t to ash whether sulforaphane could block c ical carngeness. In this paper we report that sulfphane and three synthetic analogues, designed as potent phase 2 enzyme inducers, block the formation of ammary tumors in Sprague4Dawley rats treated with single doses of 9,10-dimethyl-1,2-benzanthracene. The anaogues are exo-2-acety-exo-6-isothiocyanatoorbornane, endo-2-acetyl-exo-6-isothiocyanatonorbornane, and exo-2-acetyl-exo-5-isothiocyanatonorbornane. When sulforaphane and exo-2-acetyl-ero-6-isothicyanatonorbornane were administered by gavage (75 or 150 amol per day for 5 days) around the time of exposure to the carcinogen, the incidence, multipcty, and weight ofmammary tumors were g ntly reduced, and their development was delayed. The anages endo-2-acetyl-exo-6-isothocyanatonorbornane and exo-2-acetyl-exo-5-iothlocyanatonorbornane were less potent protectors. Thus, a class of functioalized isotdocyanates with an rcgenic Properties has been identified. These results validate the thesis that inducers of phase 2 enzymes in cultured cells are likely to protect against carcinogenesis.
Enzymes that metabolize xenobiotics play a major role in regulating the toxic, mutagenic, and neoplastic effects ofchemical carcinogens. Much evidence indicates that the activities of phase 2 detoxication enzymes (e.g., glutathione transferases, NAD(P)H:quinone reductase, UDP-glucuronosyltransferases, and epoxide hydrolase) in particular can modulate the response of animals and their cells to carcinogen exposure. Induction of these enzymes by a wide variety of chemicals (including components of the diet) results in protection against toxicity and neoplasia (1) . To identify such protective inducers and to measure their potencies, a simple cell culture system has been developed in our laboratory (2, 3 Sulforaphane is of interest for three reasons: (i) it occurs naturally in a widely consumed vegetable; (ii) it is a very potent inducer of phase 2 enzymes; and (iii) it is a monofunctional inducer (4)-i.e., it elevates phase 2 detoxication enzymes without significantly changing the synthesis of cytochromes P-450 (5). These findings allowed the design and the systematic synthesis of a large number of structurally related isothiocyanates (6) . It was found that the methylsulfinyl (CH3SO-) function ofsulforaphane could be replaced by a methylcarbonyl (i.e., acetyl) group without significantly affecting inducer potency and that, in the most potent inducers, the isothiocyanate function and the acetyl group were separated by three or four carbons of an aliphatic or cyclo-aliphatic chain. Several isomeric norbornyl isothiocyanates substituted with acetyl groups were found to approach or equal the potency ofsulforaphane as a phase 2 enzyme inducer (6) . The merits of these norbornyl isothiocyanates [exo-2-acetyl-exo-6-isothiocyanatonorbornane, 2; endo-2-acetyl-exo-6isothiocyanatonorbornane, 3; and exo-2-acetyl-exo-5-isothiocyanatonorbornane, 4 ] are that they can be more easily synthesized (from commercial 2-acetyl-5-norbornene) than sulforaphane and that they are probably more stable toward chemical and biological oxidationreduction reactions.
We report here that sulforaphane and synthetic cyclic isothiocyanate analogues block mammary tumor development in Sprague-Dawley rats treated with 9,1O-dimethyl-1,2-benzanthracene (DMBA) (7, 8) . These Since tumor and body weights were not measured on the animals that died during the course of the experiment, we report separately the tumor incidence and multiplicity for all rats (two rats were excluded for reasons given in Table 1 ) and for the 137 rats surviving to the termination of the experiment (Tables 1 and 2, respectively) .
The mean body weights (± SEM) of the animal groups at the beginning of treatment (age 47 days) were between 116 ± 1.7 and 126 ± 1.9 g. The final weights at termination of the experiment are given in Table 2 .
The development and characteristics of tumors in each group were assessed in four ways: (i) incidence, the fraction (percent) of animals that developed tumors; (ii) multiplicity, the total number of tumors divided by the total number of animals at risk; (iii) total number and weight of tumors removed from each animal at the termination of the experiment; and (iv) latency of tumor development. The proportions of tumor-free animals in the control and each treatment group were compared at the time of the weekly examinations of the animals (Fig. 1) .
Statistical Analysis of Results. Differences in tumor incidence were evaluated by the Fisher exact test. Tumor multiplicity differences were analyzed by a Poisson distribution model and average rates were compared. The overall progression of tumor development was assessed by KaplanMeier analyses followed by logarithmic rank tests.
Chemical Syntheses. The synthetic methods and characterization ofthe compounds have been described (6) . Multigram quantities of compounds 2-4 were prepared in one step from commercial 2-acetyl-5-norbornene (a mixture of exo and endo isomers) obtained from Aldrich.
RESULTS
Administration of sulforaphane or of the 2-acetylnorbornyl isothiocyanates 2, 3, and 4 reduced the incidence, multiplicity, and weights and delayed the development of the mammary tumors evoked by a single dose of DMBA in female Sprague-Dawley rats (Tables 1 and 2; Fig. 1 ). There were clear-cut differences in the potencies of the chemoprotective compounds.
In the control group, not receiving any protector, the incidence of mammary tumors for all animals was 68.01% (Table 1) . If the two animals that did not survive to the termination of the experiment (rat age, 202 days) were censored, the tumor incidence in the control group was very similar, 65.2% ( 0.40t (25.6) A total of 145 rats were entered into the experiment. Each received 8 mg of DMBA at age 50 days. There were initially 25 controls and 20 animals in each of the six treated groups. The above analysis is based on 143 animals (see below). *P < 0.05 for differences from controls (Fisher exact test). tP < 0.01 for differences from controls (Poisson distribution model).
tOne rat died immediately after gavage and is not included.
§One rat died without palpable tumors at age 167 days and is not included.
Proc. Nati. Acad. Sci. USA 91 (1994) 0.016 and 0.0022 at low and high doses of sulforaphane, respectively) ( Fig. 1 ). Norbornyl isothiocyanate 2 was an equally potent chemoprotector at the 75-and 150-jLmol doses, irrespective of whether incidence, multiplicity, tumor weight, or latency of tumor development was considered (Tables 1 and 2; Fig. 1 ). With these doses the protective effect appears to have attained a plateau. Since 75-pumol doses of compound 2 reduced tumor incidence and multiplicity even more markedly than the same dose of sulforaphane, it is possible that 2 may be a more potent chemoprotector than sulforaphane.
Compounds 3 and 4, both tested at five doses of 100 pmol, also blocked tumor formation, but these effects did not reach statistical significance for some indicators of protection (Tables 1 and 2). Thus, compound 3 was clearly the least potent Compound 4: 100 Mmol (P = 0.023). Kaplan-Meier incidence curves were analyzed by the logarithmic rank test. The P values refer to comparisons of differences in rate of tumor development in treated and control groups. All differences between treated and control groups are significant except for compound 3. It is therefore gratifying that measurements of inducer potencies in our cell culture assay not only correctly predicted anticarcinogenic activity but also provided a reasonable index of potency.
The reasons for the apparent differences in potencies of the compounds tested are not clear. The possibly higher potency of 2 in comparison to sulforaphane might be attributed to the fact that the isothiocyanate group of 2 is secondary whereas that of sulforaphane is primary. Consequently, the former is likely to be less reactive and might therefore resist metabolic disposal or other promiscuous intracellular reactions with nucleophiles to which all isothiocyanates are susceptible. The differences in potencies of 2, 3, and 4 are more difficult to explain. In compounds 2 and 4 the functional groups are exo, whereas in compound 3 the 2-acetyl group is endo and, therefore, more protected. One aspect of this structureactivity relation is noteworthy: the nearly equivalent effects of methylsulfmyl (CH3SO-) and methylcarbonyl (CH3CO-) functions on both inducer and chemoprotective potencies of these agents.
The mechanisms of the chemoprotective actions of these compounds are not fully understood. Although isothiocyanates induce protective phase 2 enzymes, and the functionalized isothiocyanates used in these experiments are especially potent in this regard, it is becoming increasingly clear that some isothiocyanates also block activation of carcinogens by inhibiting phase 1 enzymes (10, 13). Whether sulforaphane and the 2-acetylnorbonyl isothiocyanates inhibit carcinogen activation is not known. Clearly, agents that are monofunctional inducers of phase 2 enzymes and block carcinogen activation by inhibiting phase 1 enzymes are likely to be ideal chemoprotectors.
